Kyverna Therapeutics, Inc. Common Stock Net Assets
Kyverna Therapeutics, Inc. Common Stock net assets. Based on the latest financial reports, Kyverna Therapeutics, Inc. Common Stock (KYTX) has net assets worth $195.58 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($257.02 Million) and total liabilities ($61.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Kyverna Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $195.58 Million |
| % of Total Assets | 76.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 210.31 |
Net Assets of Kyverna Therapeutics, Inc. Common Stock (2021–2025)
Net assets of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. This chart illustrates how Kyverna Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See Kyverna Therapeutics, Inc. Common Stock (KYTX) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
The table below shows the annual net assets of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. For live market cap and overall valuation, see Kyverna Therapeutics, Inc. Common Stock (KYTX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $232.28 Million | -12.87% |
| 2024-12-31 | $266.59 Million | +442.10% |
| 2023-12-31 | $49.18 Million | +5.36% |
| 2022-12-31 | $46.68 Million | +200.91% |
| 2021-12-31 | $-46.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kyverna Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37804300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Kyverna Therapeutics, Inc. Common Stock Net Assets Breakdown (December 2025)
Kyverna Therapeutics, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $97.00K | 0.04% |
| Other Components | $657.00 Million | 282.86% |
| Total Equity | $232.28 Million | 100.00% |
Kyverna Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Kyverna Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Barings Corporate Investors
NYSE:MCI
|
$344.72 Million |
|
Seanergy Maritime Holdings Corp
NASDAQ:SHIP
|
$344.74 Million |
|
Magna Mining Inc
V:NICU
|
$344.75 Million |
|
Beijing Kaiwen Education Technology Co Ltd
SHE:002659
|
$344.94 Million |
|
Jinhong Fashion Group Co Ltd
SHG:603518
|
$344.65 Million |
|
Guangzhou Jinzhong Auto Parts Manufacturing Co. Ltd.
SHE:301133
|
$344.65 Million |
|
Talgo SA
MC:TLGO
|
$344.56 Million |
|
Energiekontor AG
F:EKT
|
$344.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kyverna Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 266,587,000 to 232,276,000, a change of -34,311,000 (-12.9%).
- Net loss of 161,307,000 reduced equity.
- New share issuances of 140,608,000 increased equity.
- Other comprehensive income decreased equity by 8,000.
- Other factors decreased equity by 13,604,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-161.31 Million | -69.45% |
| Share Issuances | $140.61 Million | +60.53% |
| Other Comprehensive Income | $-8.00K | -0.0% |
| Other Changes | $-13.60 Million | -5.86% |
| Total Change | $- | -12.87% |
Book Value vs Market Value Analysis
This analysis compares Kyverna Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.08x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-1.79 | $5.67 | x |
| 2022-12-31 | $1.81 | $5.67 | x |
| 2023-12-31 | $0.07 | $5.67 | x |
| 2024-12-31 | $6.95 | $5.67 | x |
| 2025-12-31 | $5.25 | $5.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kyverna Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.26x
- Recent ROE (-69.45%) is below the historical average (-60.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -465.88% | 0.07x | 0.00x | $-21.72 Million |
| 2022 | -61.90% | -411.29% | 0.10x | 1.43x | $-33.56 Million |
| 2023 | -122.75% | 0.00% | 0.00x | 1.53x | $-65.28 Million |
| 2024 | -47.82% | 0.00% | 0.00x | 1.14x | $-154.14 Million |
| 2025 | -69.45% | 0.00% | 0.00x | 1.26x | $-184.53 Million |
Industry Comparison
This section compares Kyverna Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | $195.58 Million | 0.00% | 0.31x | $344.71 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product ca… Read more